Jury awards Bos Sci $19.5M for Cordis stent infringement
A jury in the District Court for the District of Delaware found that Cordis, a Johnson & Johnson company, owed Boston Scientific approximately $19.5 million for infringing its Jang stent patent, which covers intellectual property associated with coronary stent technologies.
Specifically, the jury awarded $18.5 million in lost profits and $1 million in reasonable royalties to Boston Scientific.
The Natick, Mass.-based Boston Scientific brought suit against Cordis for patent infringement in December 2009, shortly after the U.S. launch of Cordis' 2.25 mm Cypher stent. On April 13, the Delaware Court ruled that, as a matter of law, Cordis infringed Boston Scientific's Jang patent and later found that Cordis' infringement was willful.
In February 2010, the company settled three cardiovascular stent patent disputes with Johnson & Johnson for $1.73 billion, one of which involved the Jang stent.
"We are pleased to see the jury recognize the value of our intellectual property," said Hank Kucheman, executive vice president and group president of cardiology, rhythm and vascular for Boston Scientific. "This is an important outcome in protecting our market position in small-vessel, drug-eluting stents against infringing products."
Specifically, the jury awarded $18.5 million in lost profits and $1 million in reasonable royalties to Boston Scientific.
The Natick, Mass.-based Boston Scientific brought suit against Cordis for patent infringement in December 2009, shortly after the U.S. launch of Cordis' 2.25 mm Cypher stent. On April 13, the Delaware Court ruled that, as a matter of law, Cordis infringed Boston Scientific's Jang patent and later found that Cordis' infringement was willful.
In February 2010, the company settled three cardiovascular stent patent disputes with Johnson & Johnson for $1.73 billion, one of which involved the Jang stent.
"We are pleased to see the jury recognize the value of our intellectual property," said Hank Kucheman, executive vice president and group president of cardiology, rhythm and vascular for Boston Scientific. "This is an important outcome in protecting our market position in small-vessel, drug-eluting stents against infringing products."